Big things are stirring in the biotech sector, and it’s got me incredibly bullish on the opportunity to make a lot of money here. I’ve made it pretty clear that I see long-term, revolutionary potential in investments like select cryptocurrencies.
But in the meantime, 2020 could easily go down as The Year of Biotech…
This year marks the 20th anniversary of the project to sequence the first human genome. We could see quite the celebration, as researchers’ efforts to develop new drugs in a variety of categories are starting to pay off in amazing ways.
I’m talking about plans to “fix” errors in our genetic code that can lead to awful and painful maladies, like sickle cell disease. Or engineering special immune cells from within our own bodies to deliver targeted cancer treatments — a process known as immunotherapy.
These breakthrough treatments are finally starting to gain approval by the FDA and make their way into the mainstream conversation after decades of research and clinical trials.
I recommend specific gene editing and other biotech plays to my subscribers because of the dramatic upside potential ahead. Radical new treatments coming onto the market could change the way we treat deadly diseases like cancer.
But it’s even more than that. It’s also about the growing earnings and stronger stock performance of the best plays in this dynamic sector.
After mostly sideways movement earlier in the year, the market started to take notice too, beginning in October.
In the 2019 chart below, you can see how the Nasdaq Composite (the orange line) started to break away from the biotech sector, represented by the industry bellwether exchange-traded fund (ETF), the iShares Nasdaq Biotechnology ETF (IBB, the blue line).
If you look closely, you’ll see that this divergence started happening in April, the same month that Sen. Bernie Sanders filed his Medicare for All Act in the U.S. Senate.
Such a law could drastically cut drug prices and hit the biotech sector where it hurts. The heated political climate surrounding this issue certainly didn’t help biotech stocks for most of last year.
We saw a similar situation play out in the ramp up to the 2016 presential election, when Hilary Clinton began talking negatively about price hikes for pharmaceuticals in the wake of scandals surrounding firms like Valeant Pharmaceuticals – now Bausch Health (BCH) – and Turing Pharmaceuticals.
Folks mostly steered clear of the sector for the past four years or so. The iShares Nasdaq Biotechnology ETF went nowhere.
But look at that first chart again to see what started happening in 2019. Biotech stocks showed new signs of life.
The SPDR S&P Biotech ETF (XBI) climbed 32% last year, closing 2019 with a new 52-week high following a wave of acquisition deals sweeping over the sector.
Several of the world’s largest biotech juggernauts are snapping up smaller firms that specialize in treatments for cancer and autoimmune disorders. The major players in this industry don’t want to miss out on what’s coming down the pike, especially when many of them rely on profits from older drug patents that are set to expire.
By 2024, research firm EvaluatePharma expects the global cancer-drugs market will nearly double from $123 billion today.
The FDA has also begun approving new cancer drugs after smaller, quicker, and less-costly clinical trials — a win for the industry. Plus, health insurance plans have shelled out top dollar for some of these expensive treatments that can cost $100,000 or more per year.
As they buy up smaller biotech firms and their products, individual drug companies are also looking to establish multiple therapies for specific diseases that work better in the outcomes-based payment model the government is starting to take.
There are a lot of catalysts joining forces behind this sector right now, but there’s another one on the horizon that I believe could send biotechs soaring into the stratosphere.
You see, if President Trump wins his reelection bid in November, it will be a huge win for the biotech industry. In that case, we’ll likely see FDA approvals increase and drug prices maintain their healthy level.
But even if he doesn’t, it’s unlikely a Medicare for All type of law passes through Congress. Polling by the Kaiser Family Foundation shows that even Democrats and Democratic-leaning independents largely prefer more incremental changes to healthcare.
Biotech’s Big Year
Mark my words — 2020 will be the year of biotech.
Of course, not every biotech stock will make you money next year. You’ll still need to know how to play this highly complex market to your advantage.
This is true in biotech, and it’s true in other sectors as well. There are big opportunities ahead in 2020 if you know where to find them.
That’s why I am so excited to join forces with my good friend and fellow InvestorPlace colleague Louis Navellier. We’ve built our careers using different methodologies to identify big winners. We’ve combined my big picture “top down” approach with Louis’ quantitative, numbers-driven “bottom up” style.
And together we unveiled our thoughts on 2020 and what you need to do to set yourself up for what we both expect will be a major year for stocks.
We’ve also come up with stocks that our two systems have identified as on the verge of major breakouts this year. One is a biopharmaceutical company that develops medications needed by large patient populations, which fits right into the hypergrowth trends I follow. Louis also sees big potential because the company meets his strict quantitative growth criteria.
You can watch our full discussion here at our Early Warning Summit 2020. We’ve just added two new stock picks for the joint project we announced there – our Power Portfolio – so I hope you’ll take a moment to watch it now.
I’m not hearing this kind of analysis and discussion anywhere else, and I’m afraid too many investors are going to miss out on what’s to come. I don’t want that to be you.
P.S. To our knowledge, nothing like this has ever been done before. We think it’s truly a game changer for folks.
Louis and I handpicked 10 stocks that we believe will be the biggest winners of 2020. We call them our Power Portfolio. And in just one month, five are up by double-digits! Now we’ve just added two new under-the-radar stocks with big potential.
What makes our Power Portfolio a game changer is the highly selective nature of these stocks. Basically, only one out of 500 stocks meet BOTH our strict requirements.
These stocks are best-in-class and currently screaming buys for 2020. They are the cream of the crop in terms of all the qualities that drive stock price gains.
Click here to learn more so you can be in the best positioned stocks for the year ahead.
Matt McCall’s MoneyLine Podcast
Click here to listen to Matt McCall’s MoneyLine podcast! This week, Matt lays out his strategy for the current market environment and the next 10 years. Then, he dives into the world of altcoins. Even though bitcoin has been rallying, the altcoins are where the real money is being made. Finally, Matt takes a subscriber question and pleas to investors to change their way of thinking.
You can subscribe to this podcast on iTunes, Stitcher, Spotify, or wherever you listen to podcasts.
Learn where Matt McCall sees
huge investment opportunities right now:
The car as we know it is on the verge of a transformative change not seen since Karl Benz invented it nearly 135 years ago. In fact, the whole transportation sector is now poised for its version of 2.0.
I’m not exaggerating when I say this will lead to trillions of dollars in money sloshing around in the coming decades. What is coming will create one of the five biggest investment opportunities you’ll ever see in your life, no matter when you were born. Learn more here.
Marijuana has been outlawed most everywhere for decades… but now a wave of legalization is starting to sweep the world. This will create massive new markets and massive stock market winners. Learn more here.
The next big breakthrough in battery technology is an innovation that will have multi-trillion-dollar economic implications. I can tell you this mega innovation isn’t a matter of “if,” it’s a matter of “when,” and I believe it will go down as one of the greatest inventions of the 21st century.
Those on the right side of this innovation stand to build incredible wealth… just like people did from the creation of the internet and the smartphone. Think of this as your “field guide” for profiting from the next big battery breakthrough. Learn more here.